Shingrix Orders Limited by GlaxoSmithKline
June 22, 2018
Source: FiercePharma
675
In wake of getting the green light from the FDA and a preferential recommendation from CDC vaccine advisers, GlaxoSmithKline’s new shingles vaccine Shingrix took the market by storm. This has, however, led to the Pharma giant facing some restrictions and have thus placed TV advertising for the product on hold.
Order limits have been introduced by GSK owing to high demand for the product, as per a note on the CDC’s website. In the meantime, shipping delays are being experienced by providers and according to the CDC, the delays are likely to remain throughout the year.
The CDC further stated that GSK's U.S. supply has been boosted by through the end of 2018. The company plans to release medicine stocks to all types of customers for the rest of 2018 on a "consistent and predictable schedule".
The increase in uptake and the restricted supply could be triggered by the fact that Glaxo’s Shingrix is seen as a better alternative compared to Merck’s older Zostavax. A GSK spokesman stated that Shingrix has seen larger-than-expected demand during its launch
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Disposable Medical Products that Keep Your Medical Facility Clean and Sterile March 31, 2022
- 10 Triumphant Drug Launches Of The Decade August 26, 2021
- NICE turns down GSK’s IV Benlysta for systemic lupus June 4, 2021
- EC clears GSK’s Benlysta for lupus nephritis May 10, 2021
- GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage March 12, 2021
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
